AC
REGN icon

AIFG Consultants’s Regeneron Pharmaceuticals REGN Stock Holding History

AIFG Consultants’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-444
Closed -$428K – 50
2024
Q1 		$428K Buy
444
+2
+0.5% +$1.9K 0.31% 25
2023
Q4 		$388K Buy
442
+3
+0.7% +$2.47K 0.3% 26
2023
Q3 		$365K Buy
+439
New +$345K 0.3% 25

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

AIFG Consultants's REGN Position: Q2 2024 in Review

AIFG Consultants sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 444 shares — an estimated $428K sold.

AIFG Consultants first reported a position in REGN in Q3 2023 and held it in 3 quarters. The position peaked at $428K in Q1 2024. 1,331 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • AIFG Consultants reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • AIFG Consultants sold 444 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $428K.
  • AIFG Consultants first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • AIFG Consultants's Regeneron Pharmaceuticals position peaked at $428K in Q1 2024.
  • 1,331 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on AIFG Consultants's 13F filing for Q2 2024, filed 29 Jul 2024.